Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

luminespib (AUY922)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Ligand

Drug class:

HSP90 inhibitor

Related drugs:

ALK positive	Non Small Cell Lung Cancer	ALK positive	Non Small Cell Lung Cancer	AUY922 Sensitive: C2 – Inclusion Criteria AUY922 Sensitive : C2	AUY922 Sensitive: C2 – Inclusion Criteria AUY922 Sensitive : C2
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	AUY922 Sensitive: C2 – Inclusion Criteria AUY922 Sensitive : C2	AUY922 Sensitive: C2 – Inclusion Criteria AUY922 Sensitive : C2
ALK rearrangement	Non Small Cell Lung Cancer	ALK rearrangement	Non Small Cell Lung Cancer	AUY922 Sensitive: C2 – Inclusion Criteria AUY922 Sensitive : C2	AUY922 Sensitive: C2 – Inclusion Criteria AUY922 Sensitive : C2
EGFR T790M	Non Small Cell Lung Cancer	EGFR T790M	Non Small Cell Lung Cancer	AUY922 Sensitive: C2 – Inclusion Criteria AUY922 Sensitive : C2	AUY922 Sensitive: C2 – Inclusion Criteria AUY922 Sensitive : C2
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	AUY922 Sensitive: C3 – Early Trials AUY922 Sensitive : C3	AUY922 Sensitive: C3 – Early Trials AUY922 Sensitive : C3
NPM1-ALK I1171T	Non-Hodgkin’s Lymphoma	NPM1-ALK I1171T	Non-Hodgkin’s Lymphoma	AUY922 Sensitive: D – Preclinical AUY922 Sensitive : D	AUY922 Sensitive: D – Preclinical AUY922 Sensitive : D
NPM1-ALK F1174C	Non-Hodgkin’s Lymphoma	NPM1-ALK F1174C	Non-Hodgkin’s Lymphoma	AUY922 Sensitive: D – Preclinical AUY922 Sensitive : D	AUY922 Sensitive: D – Preclinical AUY922 Sensitive : D